The Hollings Cancer Center's (HCC) Protocol Review and Monitoring System oversees and ensures the scientific merit, priorities and progress of all cancer clinical studies conducted at the Medical University of South Carolina (MUSC). An HCC Protocol Review Committee (PRC), appointed by the HCC Director and administratively supported by the HCC Clinical Trials Office (CTO), has been given the authority and charge to carry out this mandate. Additionally, the HCC disease-based working groups assist the PRC by virtue of their responsibility for the prioritization of potentially competing clinical trials. The primary goal of the PRC is to ensure that investigator- and industry-initiated cancer research studies nvolving human subjects conducted at MUSC are: 1) scientifically and statistically sound;2) appropriately designed;3) feasible for completion;and 4) in compliance with NIH guidelines for human studies. It also plays an important role in mediating competing studies by requiring an agreed upon institutional prioritization alan, and it closely monitors the accrual progress of studies.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA138313-04
Application #
8377251
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2012-04-01
Budget End
2013-03-31
Support Year
4
Fiscal Year
2012
Total Cost
$67,752
Indirect Cost
$21,818
Name
Medical University of South Carolina
Department
Type
DUNS #
183710748
City
Charleston
State
SC
Country
United States
Zip Code
29425
Bai, Aiping; Bielawska, Alicja; Rahmaniyan, Mehrdad et al. (2018) Dose dependent actions of LCL521 on acid ceramidase and key sphingolipid metabolites. Bioorg Med Chem 26:6067-6075
Graboyes, Evan M; Kompelli, Anvesh R; Neskey, David M et al. (2018) Association of Treatment Delays With Survival for Patients With Head and Neck Cancer: A Systematic Review. JAMA Otolaryngol Head Neck Surg :
Burris, Jessica L; Rivera-Rivera, Jessica N; Armeson, Kent et al. (2018) Causal attributions and their impact on psychosocial functioning in head and neck cancer patient-caregiver dyads: a preliminary, longitudinal study. Qual Life Res :
Bea, Vivian J; Cunningham, Joan E; Alberg, Anthony J et al. (2018) Alcohol and Tobacco Use in an Ethnically Diverse Sample of Breast Cancer Patients, Including Sea Island African Americans: Implications for Survivorship. Front Oncol 8:392
Panneer Selvam, Shanmugam; Roth, Braden M; Nganga, Rose et al. (2018) Balance between senescence and apoptosis is regulated by telomere damage-induced association between p16 and caspase-3. J Biol Chem 293:9784-9800
Wrangle, John M; Velcheti, Vamsidhar; Patel, Manish R et al. (2018) ALT-803, an IL-15 superagonist, in combination with nivolumab in patients with metastatic non-small cell lung cancer: a non-randomised, open-label, phase 1b trial. Lancet Oncol 19:694-704
Janakiraman, Harinarayanan; House, Reniqua P; Gangaraju, Vamsi K et al. (2018) The Long (lncRNA) and Short (miRNA) of It: TGF?-Mediated Control of RNA-Binding Proteins and Noncoding RNAs. Mol Cancer Res 16:567-579
Jin, Junfei; Lu, Zhongyang; Li, Yanchun et al. (2018) LPS and palmitate synergistically stimulate sphingosine kinase 1 and increase sphingosine 1 phosphate in RAW264.7 macrophages. J Leukoc Biol 104:843-853
Joseph, Anne M; Rothman, Alexander J; Almirall, Daniel et al. (2018) Lung Cancer Screening and Smoking Cessation Clinical Trials. SCALE (Smoking Cessation within the Context of Lung Cancer Screening) Collaboration. Am J Respir Crit Care Med 197:172-182
Rojewski, Alana M; Tanner, Nichole T; Dai, Lin et al. (2018) Tobacco Dependence Predicts Higher Lung Cancer and Mortality Rates and Lower Rates of Smoking Cessation in the National Lung Screening Trial. Chest 154:110-118

Showing the most recent 10 out of 536 publications